The Endocannabinoid System and the Brain: Mechoulam's Masterwork Review
The endocannabinoid system and the brain.
The founder of cannabinoid science authored the definitive review of how your body's own cannabis-like molecules regulate anxiety, mood, memory, appetite, and nearly every other brain function.
Your body is running on cannabis right now.
Not the plant. Your brain is producing its own cannabis-like molecules — endocannabinoids — every second of every day. They regulate your mood as you read this sentence. They modulate the pain signals from wherever you're sitting. They're involved in whether you feel hungry, anxious, sleepy, or focused. They shaped the memories you formed yesterday and the ones you're forming now.
This is the endocannabinoid system. It exists in every vertebrate animal. It has been conserved for over 500 million years of evolution. And until Raphael Mechoulam's work, nobody knew it existed.
In 2013 — nearly fifty years after isolating THC and two decades after discovering anandamide — Mechoulam published his masterwork: a comprehensive review of what the endocannabinoid system does in the brain, written for the Annual Review of Psychology. It remains the single best entry point for understanding why cannabis affects the mind the way it does.
Why Psychology?
The choice of journal was deliberate and revealing. Mechoulam was a chemist. He could have published this review in a pharmacology journal, a neuroscience journal, or a general science journal. Instead, he chose the Annual Review of Psychology — one of the most prestigious and selective review series in the behavioral sciences, where authors are invited, not applicants.
The message was clear: the endocannabinoid system isn't a pharmacological curiosity. It's a fundamental brain system, as important to understanding human psychology as the dopamine, serotonin, or GABA systems. It governs the functions that most directly shape subjective experience — anxiety, mood, memory, reward, and the capacity to learn.
Mechoulam co-authored the review with Linda Parker, a neuroscientist at the University of Guelph in Ontario who had spent years studying how the ECS regulates nausea, vomiting, and conditioned responses. Together, they covered seven major domains of brain function.
The Seven Domains
The breadth is staggering. This isn't a system that does one thing. It's a regulatory layer that sits on top of virtually every major brain function, fine-tuning the balance between too much and too little activity. When the ECS works properly, you don't notice it — anxiety stays manageable, memories form and fade appropriately, reward feels proportionate to effort. When it's disrupted, everything shifts.
The Biphasic Paradox
The most important insight in the review — the one that explains more about cannabis than almost any other finding — is that the endocannabinoid system is consistently biphasic.
This single concept explains a remarkable number of cannabis phenomena:
Why cannabis "stopped working" for your anxiety. At first, a small amount of THC supplemented your endocannabinoid signaling, reducing anxiety. As tolerance developed and doses escalated, you crossed from the therapeutic zone into the harmful one. The same drug, the same receptors, the opposite effect.
Why some people get paranoid and others don't. Individual differences in baseline endocannabinoid tone, CB1 receptor density, and FAAH enzyme activity mean that the same dose of THC pushes different people to different points on the biphasic curve.
Why withdrawal hits so many systems at once. Chronic THC use downregulates CB1 receptors across the brain. When you stop, endocannabinoid signaling drops below the normal baseline in all seven domains simultaneously. Anxiety spikes. Sleep collapses. Appetite disappears. Mood destabilizes. Memory feels foggy. It's not seven separate problems — it's one system failing across seven functions.
How It Actually Works
This is why the comparison between endocannabinoids and THC matters so much. Your body's own system is precise — endocannabinoids are made on demand, act locally, and are degraded within seconds. THC from cannabis does the opposite: it floods every CB1 receptor in the brain simultaneously, for hours, regardless of whether any particular circuit needs modulation.
Myth vs. Reality
THC does the same thing as your body's own endocannabinoids, just from outside.
THC activates the same receptors, but the signaling pattern is fundamentally different. Endocannabinoids are synthesized on demand at specific synapses, act for seconds, and are rapidly degraded. THC arrives everywhere at once, activates receptors that don't need activating, and persists for hours. It's like the difference between a thermostat adjusting your home temperature by one degree and someone setting every radiator in the building to maximum.
The Evidence
Endocannabinoid signaling is retrograde, on-demand, local, and transient. THC is exogenous, global, non-selective, and persistent. This difference — not the receptor binding itself — explains why chronic THC use causes problems that endocannabinoid signaling doesn't.
Mechoulam & Parker (2013); Piomelli (2003), Nat Rev Neurosci
Extinction Learning: The Therapeutic Frontier
One of the most clinically significant sections of the review concerned extinction learning — the brain's process for unlearning fear responses. When you have a traumatic experience and later learn that the trigger is no longer dangerous, that's extinction. It doesn't erase the original memory; it creates a new, competing memory that suppresses the fear response.
The ECS is critical to this process. Endocannabinoid signaling in the amygdala and prefrontal cortex facilitates extinction — helping the brain update its threat assessments. This has direct implications for PTSD, where extinction is impaired and traumatic memories remain perpetually active.
The Authors
By 2013, Mechoulam was 82 years old — and being invited to write for the Annual Review of Psychology represented something remarkable. A chemist who had spent his career in a pharmacology lab was now being asked to define how psychologists should understand the brain. His co-author, Linda Parker, brought complementary expertise. Where Mechoulam's work had been primarily molecular — isolating compounds, characterizing receptors — Parker had spent years studying how the ECS shapes behavioral responses. Her lab had done foundational work on cannabinoid regulation of nausea and vomiting, taste aversion, and conditioned responses.
Together, they wrote something neither could have produced alone: a review that translated molecular pharmacology into psychological function, bridging the gap between what the ECS is and what it means for human experience.
What It Means for Cannabis Users
The biphasic model that Mechoulam and Parker described has practical implications that most cannabis users never hear about:
Tolerance breaks aren't just about reducing tolerance. They're about allowing CB1 receptors to upregulate back to normal density — restoring the precision signaling that chronic THC exposure disrupted. Research suggests CB1 receptors begin recovering within days and substantially normalize within 2-4 weeks.
Microdosing has a pharmacological rationale. The biphasic curve means there's a dose window where cannabinoid supplementation could genuinely reduce anxiety without causing the problems associated with heavy use. The challenge is that the window is narrow and individual.
Withdrawal is temporary. The ECS is one of the oldest and most resilient biological systems in vertebrate evolution. It recovered from the asteroid that killed the dinosaurs. It will recover from your tolerance break.
Frequently Asked Questions
Cite this study
Mechoulam, Raphael; Parker, Linda A. (2013). The endocannabinoid system and the brain.. Annual review of psychology, 64, 21-47. https://doi.org/10.1146/annurev-psych-113011-143739